Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.47 |
| ▸ | FABP7 | O15540 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | RHOA | P61586 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4728768 | 0.88 | KMT2A (0.48) | KMT2AFABP5FABP7CYP3A4EPHX2 | |
| SCHEMBL30729524 | 0.88 | KMT2A (0.48) | KMT2AFABP5FABP7CYP3A4EPHX2 | |
| SCHEMBL44676 | 0.87 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL28080728 | 0.85 | KMT2A (0.47) | KMT2AFABP5FABP7CYP3A4EPHX2 | |
| SCHEMBL6444593 | 0.83 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL17130452 | 0.82 | KMT2A (0.60) | KMT2AFABP5FABP7CYP3A4EPHX2 | |
| SCHEMBL15058849 | 0.80 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL12081347 | 0.80 | KMT2A (0.52) | KMT2AFABP5FABP7CYP3A4EPHX2 | |
| SCHEMBL20903881 | 0.80 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL68446 | 0.80 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240131176-A1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | SEAGEN INC (US) | 2024-04-25 | — | — | US | disclosed |
| US-20240043556-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-20230346968-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230270871-A1 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | AGENSYS, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| CN-116209464-A | Markers for use in methods of treating cancer with Antibody Drug Conjugates (ADCs) | 艾更斯司股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| EP-4168039-A1 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | Agensys, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11633500-B2 | Antibody drug conjugates (ADC) that bind to CD37 proteins | AGENSYS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11607460-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | SEAGEN INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-20230033859-A1 | CD19 BINDING AGENTS AND USES THEREOF | SEAGEN INC (US) | 2023-02-02 | — | — | US | disclosed |
| US-20230025600-A1 | TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20090093612-A1 | AMIDE-SUBSTITUTED XANTHENE DYES | EPOCH BIOSCIENCES, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2009046165-A1 | AMIDE-SUBSTITUTED XANTHENE DYES | EPOCH BIOSCIENCES, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| US-20090047348-A1 | POLY(ORGANOPHOSPHAZENE) HYDROGELS FOR DRUG DELIVERY, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-02-19 | — | — | US | disclosed |
| US-20090022683-A1 | Biodegradable and Thermosensitive Poly(Organophosphazene) Hydrogel, Preparation Method Thereof and Use Thereof | KIST (KR) | 2009-01-22 | — | — | US | disclosed |
| WO-2008153278-A1 | PHOSPHAZENE HYDROGELS WITH CHEMICAL CORSS -LINK, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008153277-A1 | POLY(ORGANOPHOSPHAZENE) HYDROGELS FOR DRUG DELIVERY, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-12-18 | — | — | WO | disclosed |
| EP-2001513-A1 | THERMOSENSITIVE POLYPHOSPHAZENE-BIOACTIVE MOLECULE CONJUGATES, PREPARATION METHOD THEROF AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2008-12-17 | — | — | EP | disclosed |
| EP-1981544-A2 | BIODEGRADABLE AND THERMOSENSITIVE POLY(ORGANOPHOSPHAZENE) HYDROGEL, PREPARATION METHOD THEREOF AND USE THEREOF | KIST Korea Institute of Science and Technology (KR) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007114549-A1 | THERMOSENSITIVE POLYPHOSPHAZENE-BIOACTIVE MOLECULE CONJUGATES, PREPARATION METHOD THEROF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007083875-A2 | BIODEGRADABLE AND THERMOSENSITIVE POLY(ORGANOPHOSPHAZENE) HYDROGEL, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11607460-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | MTOR, RICTOR, PIK3R5 | KMT2A 1943/4885FABP5 3509/4885FABP7 3887/4885 |
| US-20240131176-A1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | MTOR, RICTOR, PIK3R5 | KMT2A 1943/4885FABP5 3509/4885FABP7 3887/4885 |
| US-20240043556-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | LGALS3BP, PABPC4, PA2G4 | KMT2A 2170/4885FABP5 465/4885FABP7 11/4885 |
| US-20090022683-A1 | Biodegradable and Thermosensitive Poly(Organophosphazene) Hydrogel, Preparation Method Thereof and Use Thereof | PHOSPHO1, PGLS, LIPE | KMT2A 4069/4885FABP5 827/4885FABP7 324/4885 |
| US-20230025600-A1 | TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | CD2BP2, FOLH1, SPAG5 | KMT2A 915/4885FABP5 883/4885FABP7 2330/4885 |
| US-20090047348-A1 | POLY(ORGANOPHOSPHAZENE) HYDROGELS FOR DRUG DELIVERY, PREPARATION METHOD THEREOF AND USE THEREOF | PHOSPHO1, PGLS, NAPEPLD | KMT2A 4264/4885FABP5 2144/4885FABP7 828/4885 |
| US-11633500-B2 | Antibody drug conjugates (ADC) that bind to CD37 proteins | SIGLEC7, FUT7, SLC17A5 | KMT2A 1277/4885FABP5 468/4885FABP7 114/4885 |
| US-20090093612-A1 | AMIDE-SUBSTITUTED XANTHENE DYES | ANXA5, PHOSPHO1, TPST2 | KMT2A 2030/4885FABP5 494/4885FABP7 1548/4885 |
| US-20230270871-A1 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | CD44, CD2BP2, EPCAM | KMT2A 1177/4885FABP5 687/4885FABP7 1841/4885 |
| US-20230346968-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | IGSF11, CD2BP2, PA2G4 | KMT2A 1044/4885FABP5 764/4885FABP7 1240/4885 |
| US-20230033859-A1 | CD19 BINDING AGENTS AND USES THEREOF | BCL6B, CD22, BCL6 | KMT2A 920/4885FABP5 475/4885FABP7 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.